Key Takeaways
- Dental practices have two distinct 2026 values: one for private doctor-to-doctor buyers (typically 4.0–6.5× SDE or 70–85% of collections) and one for DSO/private-equity buyers (5–11×+ adjusted EBITDA depending on practice size).
- Scale can drive valuation more than specialty; crossing from $1–3 million to $3–5 million in adjusted EBITDA can add approximately two turns to the multiple.
- Owner dependency, hygiene revenue share, EBITDA margin, documented SOPs, and payer/lease mix can be some of the main factors that move a practice within its valuation tier.
- Private-buyer transactions often provide faster exits and higher cash certainty, while DSO deals can deliver higher headline numbers that frequently include equity, earnouts, and 3–5 year employment agreements.
- McLerran & Associates provides side-by-side valuations across both buyer markets using CPA-led, diligence-grade EBITDA analysis to help owners compare transition paths.
Schedule a Free Discovery Call with McLerran & Associates
How Many Times EBITDA Is A Dental Practice Worth In 2026?
In 2026, most institutional buyers express dental practice valuation as a multiple of EBITDA (earnings before interest, taxes, depreciation, and amortization, or operating profit after normalizing for owner pay and one-time costs). Private doctor-to-doctor buyers more often talk in terms of a percentage of annual collections or a multiple of SDE (seller’s discretionary earnings, or total cash available to a single owner-operator). Buyer type, practice scale, and profitability shape the applicable range.
For private doctor-to-doctor transactions, McLerran & Associates’ 2026 dental valuation research places solo and two-doctor practices at approximately 4.0–6.5× SDE. On a collections basis, most private deals land at 70–85% of annual collections, within a full range of 60–95%, per DDSmatch’s 2025 valuation guidance cited in the same analysis.
For DSO and private-equity buyers, the multiple applies to adjusted EBITDA, not SDE, and it scales materially with practice size. FOCUS Investment Banking’s 2026 dental EBITDA multiples benchmarks show one pattern clearly: the bigger the earnings base, the higher the multiple. The tiers break down like this:
- Practices under $1 million in adjusted EBITDA (small DSO tuck-ins or individual buyers): approximately 5–7× EBITDA
- Regional DSO add-ons with $1 million–$3 million in adjusted EBITDA: approximately 7–9× EBITDA
- Emerging platform buyers with $3 million–$5 million in adjusted EBITDA: approximately 9–11× EBITDA
- Institutional platform buyers at $5 million-plus in adjusted EBITDA: approximately 11× or higher in select cases
Scale moves a dental practice’s multiple more than specialty in most situations. Crossing from the $1 million–$3 million EBITDA tier into the $3 million–$5 million tier can add approximately 2 turns to the multiple, per FOCUS Investment Banking’s 2026 benchmarks. A general dentistry group with $3 million or more in EBITDA can outprice a small specialty practice. Specialty premiums, where oral and maxillofacial surgery and orthodontics typically trade 1 to 3 EBITDA turns above a general practice of similar size per McLerran & Associates’ 2026 specialty data, usually stack on top of scale rather than replacing it.
Below roughly $250,000 in adjusted EBITDA, the DSO buyer pool mostly disappears, and individual dentists tend to price on collections or SDE. For more on how these tiers interact, see How Are Dental Practice Valuation Multiples Calculated? and Dental Practice Sale Multiples: 2026 Valuation Guide.
What Percentage Of Gross Collections Is A Dental Practice Worth?
SDE and EBITDA describe earnings; collections provide the other common yardstick. For private doctor-to-doctor sales, the collections-based method remains the most common pricing framework. A buyer-side firm that pooled more than 1,100 dental practice sales from 2005 to 2019 found the average sale price landed at roughly 77% of the prior year’s collections. In 2026, the median dental practice transaction closes at 68–72% of annual gross collections, per YourExitValue’s 2026 valuation analysis.
Profitability, not revenue alone, can be one of the main factors that determines where a practice lands within that band. Two practices each collecting $1 million can differ by roughly $300,000 in value. One with 55% overhead yields meaningfully higher SDE than one running at 72% overhead. The collections percentage works well as a cross-check, but serious buyers and lenders usually underwrite on normalized earnings.
Specialty variance appears in broad patterns. Oral and maxillofacial surgery often commands the highest buyer demand of any specialty, and orthodontics draws strong institutional interest. General dentistry continues to earn aggressive, near-all-time-high valuations. Specialty dental practices such as orthodontics, oral surgery, and endodontics often sell for roughly 60–80% of annual collections, per Value Alpha’s 2026 guide, though high-demand specialty practices with strong referral networks and DSO interest can exceed 85%. That wider spread than general practices reflects the range of practice quality and buyer competition within each specialty.
McLerran & Associates values private deals on a percentage-of-revenue or multiple-of-net-cash-flow basis and DSO deals on a multiple of EBITDA. Each method fits a different path. A 5× SDE offer and a 5× EBITDA offer represent different prices, because SDE and EBITDA treat owner compensation differently. That distinction underpins the two-market framework.
SDE Vs. EBITDA And The Normalization Walkthrough
SDE (seller’s discretionary earnings) reflects the total cash available to a single owner-operator: net income plus the owner’s full compensation, personal expenses run through the practice, and one-time costs. EBITDA (earnings before interest, taxes, depreciation, and amortization) starts by resetting owner pay to a market-rate replacement dentist salary, typically around 25–32% of the owner’s personal production. Only then does it calculate earnings. Because SDE keeps the owner’s full pay in the figure, SDE can run well above adjusted EBITDA on the same practice.
Normalization means adjusting reported financials to reflect true, transferable earnings. Commonly accepted add-backs include owner compensation above a fair-market provider rate, personal expenses run through the practice (vehicle, personal travel, non-business meals), genuine one-time costs (legal settlements, equipment failures), and family payroll above market-rate value. Add-backs that buyers typically reject include ordinary supplies, lab fees, marketing, and equipment purchases labeled one-time when the practice will keep replacing them.
The risk sits in the gap between a seller’s add-back schedule and what a buyer’s diligence team will accept. According to Precision Dental Analytics, 85% of lower-middle-market deals see the price adjusted after the letter of intent. Almost none of those adjustments surprises the buyers making them. Each rejected add-back reduces EBITDA, and that reduction is multiplied by the transaction multiple to determine the purchase-price impact. On a practice valued at 7× EBITDA, $125,000 of disallowed add-backs translates to roughly $875,000 off the price.
McLerran & Associates builds a CPA-led EBITDA analysis by remotely accessing the practice’s management software, pulling production and collection reports, cross-referencing against tax returns and financials, and unpacking every add-back with documentation. The result is a diligence-grade number that holds up under buyer scrutiny, so the deal is less likely to get re-traded after the letter of intent is signed. For a deeper look at how EBITDA is constructed and defended, see Dental Practice EBITDA Valuation: Multiples & Key Factors.
Private Buyer Vs. DSO: The Same Practice Valued Both Ways
The two-market framework becomes clearest when the same practice is viewed through both lenses. Consider a general dentistry practice collecting $1.5 million annually with strong hygiene, a balanced payer mix, and an owner who produces the majority of dentistry.
Under the private-buyer lens, the valuation basis is SDE or a percentage of collections. Using the 70–85% collections band described earlier, this practice might price in a range that reflects its profitability and overhead relative to peers. The structure is typically closer to all-cash at close, often SBA-financed, with a short work-back of approximately 4–8 weeks before the seller exits.
Under the DSO lens, the valuation basis shifts to adjusted EBITDA after deducting a market-rate replacement dentist cost. DSOs calculate adjusted EBITDA after deducting a replacement dentist cost commonly estimated at roughly 25–32% of the replaced doctor’s production, which can materially reduce the earnings base before the multiple is applied. The structure is rarely all-cash. DSO offers typically lead with roughly 60–85% of total consideration paid as cash at closing, with the remainder rolled into joint-venture or holding-company equity. The selling dentist typically continues working under an employment agreement of approximately 3–5 years.
The trade-offs go beyond the headline numbers: they involve timing, certainty, and how long the owner keeps working. A private-buyer path often provides greater certainty of cash at close, a faster exit, and full independence after the work-back. A DSO path can offer a higher headline number, where one advisor estimates DSOs pay about 30% more than private buyers for a mid-sized practice large enough to attract DSO interest, yet a meaningful portion of that value may be in equity that remains illiquid until the DSO itself is sold, plus earnouts tied to post-close performance targets.
Because McLerran & Associates works both paths in roughly equal measure, it produces a true side-by-side valuation that quantifies the practice’s worth in both markets. The firm’s multi-year, multi-structure financial forecasting models real after-tax outcomes across 3-, 5-, 7-, and 10-year horizons, including conservative recapitalization assumptions, so an owner can compare paths on actual cash rather than headline numbers. Single-lane brokers who work only one path cannot credibly offer this comparison. For a full breakdown of DSO-specific multiples, see 2026 DSO Dental Practice Valuation Multiples Explained, and for a side-by-side of transition options, see Dental Practice Transition Options: Private Sale Vs. DSO.
The Five Drivers That Can Move The Multiple
Within any valuation tier, specific practice characteristics can move a multiple toward the top or bottom of its range. These factors tend to matter most in 2026 buyer diligence:
- Owner dependency. Heavy reliance on the owner-doctor can cut a dental practice’s valuation by 10–20%. When the selling dentist produces 90% or more of revenue and leaves, earnings leave too. Buyers discount for this risk, and some walk away entirely above certain thresholds.
- Hygiene revenue share. A strong hygiene program, with hygiene at 25–33% of collections and recall above 85%, supports the top of the valuation range. Hygiene below 20% of collections and declining recall tends to push toward the bottom. Hygiene revenue recurs without the doctor and transfers cleanly, so buyers often pay more for it.
- EBITDA margin. Margin gives a clear signal of how well a practice converts collections into profit. Practices below 18% EBITDA margin trade at lower multiples, while top-quartile practices with above 28% EBITDA and strong hygiene programs can command the upper end of their tier. Overhead tells the same story from the other direction. Most general dental practices run overhead around 60% of collections. Practices in the mid-50s excite buyers, while overhead above 70% raises concerns.
- Infrastructure and SOPs. Documented operating systems such as SOPs, KPI dashboards, and centralized scheduling can add 1–3 turns to a dental practice’s multiple. Digital workflows such as CBCT, intraoral scanning, and cloud-based practice management reduce buyer integration risk and often support higher pricing.
- Payer and lease mix. A Medicaid payer mix above 40% of revenue can trigger a 1–2× EBITDA discount, while a commercial or fee-for-service mix above 50% supports a higher multiple. Lease terms matter equally. A short or unassignable lease can reduce value significantly, while a long, assignable lease at market rent tends to be a positive factor.
Those five drivers explain where a practice sits within its tier. Getting to the top of that range requires a competitive process. McLerran & Associates runs a structured, auction-like bid process, typically 45–60 days and generating around 10 offers, among a vetted pool of well-qualified buyers. That competitive tension is the mechanism that surfaces the higher end of the range. The firm’s buyer pool is pre-vetted, with poorly run buyers blacklisted, so owners see the real market and negotiate from strength.
Is 2026 Still A Seller’s Market For Premier Dental Practices?
Owners of premier, Class A practices still see strong demand and valuations near all-time highs. TUSK Practice Sales’ Q3 2026 Dental Market Report concludes that 2026 remains favorable for well-positioned sellers but is not a universal seller’s market. Scarcity and quality can command premiums, while ordinary or operationally fragile practices face greater scrutiny.
More than 20 PE-backed dental platforms were seven or more years into their investment hold periods as of October 2026, which sets up a wave of recapitalizations and secondary sales that is driving strategic demand for acquisition-ready practices. More than 78% of dental practice buyers have indicated they expect to complete a recapitalization within the next 12 to 36 months, creating a structural driver of continued acquisition activity.
That national picture plays out differently by region, which is why McLerran & Associates staffs offices in Cleveland (led by Justin Klingshim, with recent closings in Ohio), Atlanta (led by Matt Sutton), Northern Virginia (led by Andrew Kobylski), Los Angeles (led by Steven Au), and Phoenix (led by Brian Carroll, covering the Mountain West). Buyer appetite, achievable cash-at-close, and payer mix dynamics vary meaningfully by market, and the firm reads those regional differences rather than applying a national average to every practice.
A realistic framing helps owners plan. A softening financial trend during the sale process is a top-three reason DSOs walk away from a dental practice acquisition, per TUSK Practice Sales’ 2026 Dental M&A Market Report. The window is open for prepared owners of strong practices, and it opens unevenly across practices with weaker trends.
How To Sanity-Check Any 2026 Offer And When To Get A Real Valuation
Every offer an owner receives in 2026 can be evaluated against a practical five-point checklist before treating it as firm:
- Confirm the valuation basis. Identify whether the multiple applies to collections, SDE, or adjusted EBITDA, because the same multiple means different things on each.
- Verify every add-back with documentation. Add-backs that cannot be substantiated will be stripped in diligence, and each dollar removed is multiplied by the transaction multiple.
- Test owner dependency and hygiene share against the benchmarks above. If the owner produces 80% or more of revenue, expect a discount or an earnout.
- Compare against more than one buyer. FOCUS Investment Banking reports that its sale preparation and marketing processes often produce offers differing by 40% or more. The spread between the best and middle offers has rarely been wider.
- Ask whether the number is likely to survive quality-of-earnings diligence. A letter of intent number that gets re-traded after diligence does not function as a real offer.
A free valuation from a lead-generation firm is typically a back-of-the-napkin number anchored low, designed to win the listing rather than to hold up under buyer scrutiny. McLerran & Associates’ CPA-led analysis is diligence-grade work done up front. The firm’s clients achieve approximately 30% higher valuations on average than owners achieve selling on their own, and McLerran transacts at roughly 85–90% of the agreed value, versus an industry norm closer to 35–40%.
The two-market framework serves as the starting point for every owner conversation at McLerran & Associates. Before choosing a path, an owner benefits from seeing both numbers calculated on the right basis, defended against the right buyer pool, and modeled across the right time horizon. That approach helps owners choose with fuller information instead of a guess.
Owners who want to find out what their practice is worth in both markets, and which path may serve their goals, can schedule a free, confidential discovery call with McLerran & Associates. Call (512) 900-7989 or email info@dentaltransitions.com, or use the button below to book a time.
Frequently Asked Questions
What Multiple Will My Practice Sell For In 2026?
The multiple for any given practice depends on buyer type, earnings basis, and scale. Private doctor-to-doctor buyers typically price on SDE or a percentage of collections, while DSO and private-equity buyers price on adjusted EBITDA. Within each buyer type, larger practices with higher EBITDA usually earn higher multiples. Owner dependency, hygiene share, payer mix, lease terms, and documented operating systems all help determine where a practice lands within its tier. A diligence-grade valuation, rather than a free estimate, provides the most reliable picture for a specific practice.
Should I Sell To A Private Buyer Or A DSO?
Practice size, profitability, and personal goals all shape the better path. Smaller premier practices in the $1–$1.5 million revenue range often fit a doctor-to-doctor sale well, with a cleaner exit and greater certainty of cash at close. Larger practices, generally $1.5 million and above, are more likely to attract DSO interest, where the headline number can be higher but a meaningful portion may be in equity or earnouts rather than cash. Owners in the middle can often go either way, and the most informed choice comes from seeing both numbers on the same practice before deciding. Owners should consult their own tax and legal advisors on the implications of each structure.
Why Pay For A Valuation When Some Firms Do It Free?
A free valuation usually functions as a lead-generation tool, a number designed to win the listing rather than to survive buyer diligence. When a buyer’s quality-of-earnings team rebuilds EBITDA from tax returns, payroll records, and practice-management reports, a weak valuation often gets adjusted down and the deal gets re-traded. A CPA-led, diligence-grade valuation done up front produces a number that holds under scrutiny, so the agreed price at the letter of intent is more likely to match the price at close. A weak valuation costs far more than any advisory fee, because the real loss is the gap between the quoted number and the check at close.
Are DSO Deals All Cash, Or Is There Equity?
Most DSO deals combine cash and equity. As noted earlier, a meaningful share of DSO consideration is cash at close, and the rest is equity or earnouts. The equity portion may be structured as rollover equity in the DSO’s holding company or joint-venture entity, earnouts tied to post-close performance, or a combination. Equity held at the holding-company level can offer a higher potential ceiling if the DSO is later sold at a premium, but it is illiquid and its value depends entirely on the DSO’s future performance. Equity held at the joint-venture level may provide distributions but typically has a lower ceiling. Up to approximately 40% of a DSO deal can be in equity rather than cash, so the headline multiple only tells part of the story. Owners should consult their own advisors on the tax treatment of each component.
Do I Have To Keep Working After I Sell?
In a DSO transaction, continued clinical work is usually part of the deal. A minimum employment agreement of approximately 3–5 years is typical, though the specific term and compensation structure vary by deal. The selling dentist continues practicing as an employee, often under a compensation model tied to production. In a private doctor-to-doctor walk-away sale, the work-back is typically much shorter, approximately 4–8 weeks, before the seller exits. A partnership or vest-out structure, where the seller transfers approximately 50% of the practice now and the remainder over time, sits between these two in terms of ongoing involvement. The right structure depends on the owner’s goals and timeline.
